aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Rating of "Buy" by Analysts

Key Points

• aTyr Pharma, Inc. has received a consensus rating of "Buy" from seven research firms, with an average 1-year target price of $20.20.
• The company recently reported a loss of ($0.22) earnings per share, missing estimates and is projected to post -0.91 earnings per share for the current year.
• Institutional investors own 61.72% of aTyr Pharma's stock, with several recent purchases increasing their stakes in the company.

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $20.20.

ATYR has been the subject of several research analyst reports. Wall Street Zen downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a research report on Saturday. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th. Finally, Wells Fargo & Company boosted their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th.

Institutional Trading of aTyr Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new stake in shares of aTyr Pharma during the fourth quarter worth $17,677,000. Octagon Capital Advisors LP lifted its holdings in aTyr Pharma by 294.7% in the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock valued at $10,727,000 after buying an additional 2,652,000 shares during the period. Geode Capital Management LLC lifted its holdings in aTyr Pharma by 126.1% in the second quarter. Geode Capital Management LLC now owns 2,098,076 shares of the company's stock valued at $10,639,000 after buying an additional 1,170,276 shares during the period. Woodline Partners LP acquired a new position in aTyr Pharma in the fourth quarter valued at $6,092,000. Finally, Millennium Management LLC lifted its holdings in aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock valued at $4,829,000 after buying an additional 1,231,052 shares during the period. Institutional investors own 61.72% of the company's stock.

aTyr Pharma Price Performance

Shares of NASDAQ ATYR traded down $0.38 during midday trading on Tuesday, reaching $5.23. The company's stock had a trading volume of 5,078,267 shares, compared to its average volume of 6,042,015. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. aTyr Pharma has a fifty-two week low of $1.67 and a fifty-two week high of $7.29. The business's 50 day moving average price is $5.36 and its two-hundred day moving average price is $4.15. The company has a market cap of $512.49 million, a P/E ratio of -6.54 and a beta of 0.94.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). On average, analysts forecast that aTyr Pharma will post -0.91 EPS for the current fiscal year.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.